Stamos was criticized for donning a bald cap in support of Coulier, who's undergoing chemotherapy treatment for cancer
Dave Coulier defended his friend and Full House co-star John Stamos, who received some sharp words from fans who thought it was insensitive of Stamos to wear a bald cap in solidarity with Coulier while he’s undergoing chemotherapy treatment for cancer.
“I’m sorry to see a bunch of negative comments as I’ve just begun my cancer journey,” Coulier wrote. “It’s our friendship (me and John) and this is how we are handling a very tough time. I’m a comedian and humor is what drives me. John knows how to cheer me up and I laughed out loud when he arrived wearing a bald cap — being a true loving friend and brother.”
The backlash spread in the comments of Stamos’ Instagram post yesterday, which contained a few photos of his recent visit with Coulier. While Stamos’ photos showed nothing but smiles, and his message nothing but support — “You’re handling this with so much strength and positivity,” he told Coulier — some people nevertheless took issue with the bald cap, criticizing it as shallow, showy, or mocking.
In dismissing the disapproving messages, Coulier spoke about how glad he was to hear from people that his “words and actions” had encouraged them to get screened for cancer. He also noted how humor has helped him not only with his own diagnosis, but the deaths of his sister, mother, and niece from cancer.
Trending Stories
During those experiences, Coulier said, “We tried to stay positive, and we made each other laugh through the worst of it. So, I’m choosing to spread the word about early cancer detection to help people. That’s just who I am.”
Coulier revealed that he’d been diagnosed with Stage 3 non-Hodgkin lymphoma earlier this month. Luckily, Coulier appeared to catch the cancer before it had spread outside of hys lymphatic system, and doctors gave the actor a curability rate of over 90 percent. Coulier said he was already undergoing chemotherapy and expected to complete his treatment by February 2025.